Vericel Corp
VCEL
查看详细走势图
36.190USD
+0.810+2.29%
收盘 02/06, 16:00（美东）报价延迟15分钟
1.83B总市值
132.80市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.29%
5天
+0.58%
1月
-8.01%
6月
-0.28%
今年开始到现在
+0.50%
1年
-39.38%
查看详细走势图
TradingKey Vericel Corp股票评分
单位: USD 更新时间: 2026-02-06操作建议
Vericel Corp当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名41/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价55.00。中期看，股价处于平稳状态。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Vericel Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Vericel Corp亮点
亮点风险
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
业绩高增长
公司营业收入稳步增长，连续3年增长44.33%
业绩转盈
公司业绩转盈，最新年度盈利美元
估值合理
公司最新PE估值132.80，处于3年历史合理位
机构减仓
最新机构持股54.31M股，环比减少7.83%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值13.88K
分析师目标
根据
7
位分析师
买入
评级
55.000
目标均价
+55.46%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Vericel Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Vericel Corp简介
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
公司代码VCEL
公司Vericel Corp
CEOColangelo (Dominick C)
网址https://vcel.com/
相关品种
